Bernhard Sixt

Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare) and Nycomed Pharma (now part of Takeda).

Since leaving Amersham, Bernhard has led several companies. He is a co‑founder of Agendia and served as its CEO from 2003 until 2011 and in 2005 founded Ipotuba, a pioneer for addressing the emerging need for pharmaceutical cryo-logistics. He also led ImmunID, an innovator in precision immuno-oncology, from 2013 until 2016.

Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University (LMU) and a PhD from the Technical University (TU), both in Munich, Germany